E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10072737 |
E.1.2 | Term | Advanced breast cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To establish whether niraparib single agent treatment in advanced BRCA1-like, HER2 negative breast cancer patients deserves to be further studied |
|
E.2.2 | Secondary objectives of the trial |
To determine objective response rate (according to RECIST v1.1 (appendix 2))
• To determine duration of response
• To determine the clinical benefit rate (CR + PR + SD ≥ 6 months)
• To determine median overall survival
• To determine safety and tolerability of niraparib single agent for BRCA1-like, HER2-negative, advanced breast cancer patients
• Translational studies, e.g. putative resistance markers, like 53BP1 protein expression, XIST gene expression, PARPi-7 and MammaPrint High1/High2 (MP1/2) signatures as biomarkers of response, genetic reversal in the case of a tumor BRCA1-mutation on tumor material obtained before start and again after progression on niraparib, and discovery studies using whole genome NGS, RNAseq etc.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Histological proof of advanced, HER2 negative breast cancer;
• The tumor must be BRCA1-like, as identified by Agendia’s RNA-based BRCAness classifier;
• Only the following patients may be referred for BRCA1-like testing: all patients that had triple negative primary breast cancer; hormone-receptor positive, HER2-negative primary breast cancer patients with a histological grade III breast cancer; Breast cancer patients carrying a BRCA1 and/or BRCA2 germ line mutation.
• Fresh frozen primary tumor sample available or metastasis accessible for fresh frozen biopsy;
• Pretreatment containing an anthracycline and/or taxane in the (neo-)adjuvant or metastatic setting received, or if not, then discussed with the patient whether it is justified to forego these treatments;
• Maximum of one prior line of chemotherapy for advanced disease;
• Age ≥ 18 years;
• Able and willing to give written informed consent;
• WHO performance status of 0, 1 or 2;
• Life expectancy ≥ 3 months, allowing adequate follow up of toxicity evaluation and antitumor activity;
• Measureable or evaluable disease according to RECIST 1.1 criteria (appendix 2);
• Minimal acceptable safety laboratory values
o ANC of ≥ 1.5 x 109 /L
o Platelet count of ≥ 150 x 109 /L
o Hemoglobin ≥ 10 g/dL (6,21 mmol/L)
o Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN, ASAT and ALAT < 2.5 x ULN
• Renal function as defined by serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min (by Cockcroft-Gault formula);
• Negative pregnancy test (urine/serum) for female patients with childbearing potential;
|
|
E.4 | Principal exclusion criteria |
• Any treatment with investigational drugs within 28 days prior to receiving the first dose of investigational treatment; or within 21 days for standard chemotherapy; or within 14 days for weekly scheduled chemotherapeutic regimens or endocrine therapy;
• Patients who have progressed on previous palliative treatment with PARP1-inhibitors, platinum compounds or high dose alkylating agents with autologous stem cell rescue, since preclinical and anecdotal clinical data in breast cancer indicate that these cancers have acquired resistance to PARP-inhibitors based on genetic reversion, epigenetic modifications, or as yet unknown mechanisms. Platinum-sensitive or PARP1-inhibitor-sensitive patients who stopped for reasons other than progression are eligible;
• Patients who received high-dose alkylating agents or platinum compounds in the (neo)adjuvant setting, unless these treatments had been received longer than 3 years ago;
• Pretreatment not containing an anthracycline and/or taxane, either in the (neo-) adjuvant or metastatic setting received, or if not, then discussed with the patient whether it is justified to forego these treatments;
• Women who have a positive pregnancy test (urine/serum) and/or who are breast feeding;
• Unreliable contraceptive methods. Women and men enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: intra-uterine devices or systems, condom or other barrier contraceptive measures, sterilization and true abstinence: see also 3.5)
• Radiotherapy within the last four weeks prior to receiving the first dose of investigational treatment; except 1x8 Gy for pain palliation then a seven days interval should be maintained;
• Patients must not have any known history of myelodysplastic syndrome (MDS) or other cytogenetic abnormality associated with MDS
• Patients must not have known persistent (> 4 weeks) ≥ Grade 2 toxicity from prior cancer therapy
• Patients must not have known ≥ Grade 3 hematological toxicity with the last chemotherapy regimen
• Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;
• Patients with an active hepatitis B or C;
• Recent myocardial infarction (< six months) or unstable angina;
• Symptomatic brain or leptomeningeal metastases. If adequately treated with resection and/or irradiation and patients are at least four weeks completely free of symptoms of these metastases with or without corticosteroids, patients could be eligible if all other in- and exclusion criteria are obeyed.
• Any medical condition not yet specified above that is considered to possibly, probably or definitely interfere with study procedures, including adequate follow-up and compliance and/or would jeopardize safe treatment.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
progression-free survival rate at 4 months |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
4 months after start treatment |
|
E.5.2 | Secondary end point(s) |
• objective response rate (according to RECIST v1.1)
• duration of response
• clinical benefit rate (CR + PR + SD ≥ 6 months)
• median overall survival
• safety and tolerability |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
•At 5 years after last treatment of last included patient |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |